Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells.
Freeman J, Baglino S, Friborg J, Kraft Z, Gray T, Hill M, McPhee F, Hillson J, Lopez-Talavera JC, Wind-Rotolo M. Freeman J, et al. Among authors: hillson j. J Viral Hepat. 2014 Jun;21(6):e1-9. doi: 10.1111/jvh.12243. J Viral Hepat. 2014. PMID: 24827902 Clinical Trial.
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group. Muir AJ, et al. Among authors: hillson j. J Hepatol. 2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022. Epub 2014 Jul 24. J Hepatol. 2014. PMID: 25064437 Clinical Trial.
M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
Ling LE, Hillson JL, Tiessen RG, Bosje T, van Iersel MP, Nix DJ, Markowitz L, Cilfone NA, Duffner J, Streisand JB, Manning AM, Arroyo S. Ling LE, et al. Among authors: hillson jl. Clin Pharmacol Ther. 2019 Apr;105(4):1031-1039. doi: 10.1002/cpt.1276. Epub 2018 Dec 4. Clin Pharmacol Ther. 2019. PMID: 30402880 Free PMC article. Clinical Trial.
First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28/ICOS antagonist, in healthy adult subjects.
Yang J, Lickliter JD, Hillson JL, Means GD, Sanderson RJ, Carley K, Tercero A, Manjarrez KL, Wiley JR, Peng SL. Yang J, et al. Among authors: hillson jl. Clin Transl Sci. 2021 Jul;14(4):1314-1326. doi: 10.1111/cts.12983. Epub 2021 Mar 2. Clin Transl Sci. 2021. PMID: 33503289 Free PMC article. Clinical Trial.
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.
Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, Tesser J, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U. Moreland L, et al. Among authors: hillson j. Arthritis Res. 2001;3(4):247-52. doi: 10.1186/ar309. Epub 2001 Apr 10. Arthritis Res. 2001. PMID: 11438043 Free PMC article. Clinical Trial.
34 results